BJUI Compass
Does gadolinium truly enhance the active surveillance of men with prostate cancer?
By Abinav Udaiyar, Navid Jabalameli and Soroush Rais‐Bahrami.
Abstract
Does gadolinium truly enhance the active surveillance of men with prostate cancer?Active surveillance (AS) is the preferred management of low-risk prostate cancer (PCa) and has expanded to some favourable intermediaterisk cases, and multiparametric MRI (mpMRI) plays a significant role in monitoring patients who are on surveillance.However, widespread adoption of serial mpMRI is challenging because of resource constraints and increased demand for prostate MRI.Biparametric MRI (bpMRI) omits the gadolinium-based dynamic contrast-enhanced (DCE) phase, retaining only the T2-weighted and diffusion-weighted
Keywords
- Prostate Cancer Diagnosis and Treatment
- gadolinium-enhanced MRI
- prostate cancer
- active surveillance
- prostate cancer detection
- Open access
Source
Published in BJUI Compass. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
